Real-World Risk of Recurrent Cardiovascular Events in Atherosclerotic Cardiovascular Disease Patients with LDL-C Above Guideline-Recommended Threshold: A Retrospective Observational Study

被引:4
作者
Mackinnon, Erin S. [1 ]
Leiter, Lawrence A. [2 ,3 ]
Wani, Rajvi J. [1 ]
Burke, Natasha [1 ]
Shaw, Eileen [4 ]
Witges, Kelcie [4 ]
Goodman, Shaun G. [2 ,3 ,5 ]
机构
[1] Amgen Canada Inc, 6775 Financial Dr 300, Mississauga, ON L5N 0A4, Canada
[2] St Michaels Hosp, Li Ka Shing Knowledge Inst, Toronto, ON, Canada
[3] Univ Toronto, Dept Med, Toronto, ON, Canada
[4] Medlior Hlth Outcomes Res Ltd, Calgary, AB, Canada
[5] Univ Alberta, Canadian VIGOUR Ctr, Edmonton, AB, Canada
关键词
Atherosclerotic cardiovascular disease; Cardiovascular events; Acute coronary syndrome; Acute myocardial infarction; PCSK9 INHIBITOR EVOLOCUMAB; SOCIETY GUIDELINES; DYSLIPIDEMIA; PREVENTION; CHOLESTEROL; EFFICACY; SAFETY; ALIROCUMAB; MANAGEMENT; DIAGNOSIS;
D O I
10.1007/s40119-024-00349-6
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: The 2021 Canadian Cardiovascular Society (CCS) guidelines recommend intensive low-density lipoprotein cholesterol (LDL-C) reduction for patients with atherosclerotic cardiovascular disease (ASCVD). For patients above LDL-C threshold on maximally tolerated statins, adding ezetimibe and/or a proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i) is recommended. This population-based, real-world study examined cardiovascular (CV) events in patients with ASCVD who are on statins and above current guideline threshold LDL-C levels. Methods: Using administrative health data in Alberta, Canada, we identified patients with myocardial infarction (MI), ischemic stroke (IS), or peripheral artery disease with LDL-C > 1.8 mmol/L on statins between April 1, 2010 and March 31, 2016. Exploratory subgroups included very high-risk patients with ASCVD shown to derive the most benefit from PCSK9i intensification as identified by the CCS guidelines, including those with acute coronary syndrome (ACS) or recent MI. Frequencies and rates of individual and composite CV events (primary outcome: MI, IS, hospitalization for unstable angina, coronary revascularization, cardiovascular death; secondary outcome: MI, IS, CV death) were calculated over follow-up. Results: The study included 32,984 patients with a mean (standard deviation) follow-up of 40.8 (21.0) months. Overall, 17.7% and 15.6% experienced a primary and secondary outcome, respectively, with rates of 5.58 and 4.83 per 100 patient-years, respectively. CV death and MI were the most common events. Subgroups with recurrent MI and comorbid diabetes exhibited higher CV event rates (23.6% and 22.2% had a primary outcome, respectively). Rates of CV events were notably high in patients with ACS or recent MI (49.4% and 54.0% had a primary outcome, respectively). Conclusion: This real-world study confirms that statin-treated high-risk patients with ASCVD and above-threshold LDL-C levels have substantial incidence of recurrent CV events. These findings reinforce the opportunity for lipid-lowering therapy intensification in high-risk patients to levels below guideline-recommended threshold in order to reduce CV risk.
引用
收藏
页码:205 / 220
页数:16
相关论文
共 50 条
[31]   History of peripheral artery disease and cardiovascular risk of real-world patients with acute coronary syndrome: Role of inflammation and comorbidities [J].
Denegri, Andrea ;
Magnani, Giulia ;
Kraler, Simon ;
Bruno, Francesco ;
Klingenberg, Roland ;
Mach, Francois ;
Gencer, Baris ;
Raeber, Lorenz ;
Rodondi, Nicolas ;
Rossi, Valentina A. ;
Matter, Christian M. ;
Nanchen, David ;
Obeid, Slayman ;
Luscher, Thomas F. .
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2023, 382 :76-82
[32]   Clinical characteristics and treatment patterns in patients with atherosclerotic cardiovascular disease with hypercholesterolemia: a retrospective analysis of a large US real-world database cohort [J].
Lahoz, Raquel ;
Seshagiri, Divyagiri ;
Electricwala, Batul ;
Achouba, Assya ;
Ding, Yingjie ;
Heo, Ji Haeng ;
Cristino, Joaquim ;
Studer, Rachel .
CURRENT MEDICAL RESEARCH AND OPINION, 2024, 40 (01) :15-25
[33]   Cardiovascular disease risk in patients with elevated LDL-C levels: FH vs. non-FH [J].
Huang, Haomin ;
Li, Lamei ;
Yang, Anni ;
Chen, Tao ;
Shi, Ganwei ;
Li, Feng ;
Wang, Luya ;
Cai, Gaojun .
FRONTIERS IN CARDIOVASCULAR MEDICINE, 2024, 11
[34]   Real-World Major Adverse Cardiovascular Events of Nicorandil and Nitrate in Coronary Heart Disease in Central China: A Retrospective Cohort Study [J].
Li, Ping ;
Chen, Juan ;
Li, Na ;
You, Xiang ;
Shen, Lan ;
Zhou, Ning .
CARDIOLOGY DISCOVERY, 2023, 3 (03) :152-158
[35]   Post-treatment level of LDL cholesterol and all-cause mortality in patients with atherosclerotic cardiovascular disease: evidence from real-world setting [J].
Luo, Fan ;
Lin, Yuxin ;
Zhang, Xiaodong ;
Li, Yanqin ;
Su, Licong ;
Zhou, Shiyu ;
Xu, Ruqi ;
Gao, Qi ;
Chen, Ruixuan ;
Guo, Zhixin ;
Nie, Sheng ;
Xu, Xin .
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2024, 31 (03) :337-345
[36]   Association of total cholesterol and atherosclerotic cardiovascular disease in patients with follicular thyroid cancer A real-world study from Chinese populations [J].
Huang, Guoding ;
Lu, Hongquan ;
Li, Meigui ;
Lv, Qiongxiu ;
Chen, Qizhu .
MEDICINE, 2021, 100 (39) :E27310
[37]   Effectiveness of adherence to lipid lowering therapy on LDL-cholesterol in patients with very high cardiovascular risk: A real-world evidence study in primary care [J].
Guglielmi, Valeria ;
Bellia, Alfonso ;
Pecchioli, Serena ;
Della-Morte, David ;
Parretti, Damiano ;
Cricelli, Iacopo ;
Medea, Gerardo ;
Sbraccia, Paolo ;
Lauro, Davide ;
Cricelli, Claudio ;
Lapi, Francesco .
ATHEROSCLEROSIS, 2017, 263 :36-41
[38]   Association between lipoprotein (a) and risk of atherosclerotic cardiovascular disease events among maintenance hemodialysis patients in Beijing, China: a single-center, retrospective study [J].
Liang, Qiaojing ;
Zhang, Guojuan ;
Jiang, Liping .
BMC NEPHROLOGY, 2024, 25 (01)
[39]   Stage 1 Hypertension and the 10-Year and Lifetime Risk of Cardiovascular Disease: A Prospective Real-World Study [J].
Peng, Xinyi ;
Jin, Cheng ;
Song, Qirui ;
Wu, Shouling ;
Cai, Jun .
JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2023, 12 (07)
[40]   Risk of cancer, cardiovascular disease, thromboembolism, and mortality in patients with rheumatoid arthritis receiving Janus kinase inhibitors: a real-world retrospective observational study using Korean health insurance data [J].
Min, Hong Ki ;
Kim, Hyeongsu ;
Jeong, Ho Jin ;
Kim, Se Hee ;
Kim, Hae-Rim ;
Lee, Sang-Heon ;
Lee, KunSei ;
Shin, Soon-Ae ;
Park, Jong Heon .
EPIDEMIOLOGY AND HEALTH, 2023, 45 :1-10